Literature DB >> 30478263

Treatment outcome and associated factors among patients with epilepsy.

Yirga Legesse Niriayo1, Abraham Mamo2, Tesfaye Dessale Kassa2, Solomon Weldegebreal Asgedom2, Tesfay Mahari Atey2, Kidu Gidey2, Gebre Teklemariam Demoz3, Seid Ibrahim2.   

Abstract

Epilepsy is a major public health problem worldwide. Despite multiple drug therapies, people with epilepsy continue to have frequent seizures. There is a dearth of data on epilepsy treatment outcome and associated factors in our setting. Therefore, the aim of this was to assess treatment outcome and associated factors among epileptic patients on follow up at the neurologic clinic of Ayder comprehensive specialized hospital, Ethiopia. A cross-sectional study was conducted on randomly selected epileptic patients. Data were collected through patient interview and review of medical records. Epilepsy treatment outcome was evaluated in terms of seizure control status in the last one year follow up period. Binary logistic regression analysis was performed to identify predictors of treatment outcome. A total of 270 patients were included. Of whom, 46.6% had controlled seizures. Whereas, 38.5%, 8.8%, and 5.9% had experienced seizure attacks 1-5 times, 6-10 times, and greater than 10 times, respectively. Alcohol consumption [adjusted odds ratio [(AOR): 14.87, 95% confidence interval (CI): 3.25-68.11], negative medication belief [AOR: 3.0, 95%CI: 1.31-6.71], low medication adherence [AOR:11.52, 95%CI: 3.25-40.82], and presence of comorbidities [AOR: 10.35, 95%CI: 4.40-24.40] were predictors of uncontrolled seizure. Our finding revealed that more than half of the epileptic patients had uncontrolled seizure. Epileptic patients with a negative medication belief, comorbidities, low medication adherence, and those who consume alcohol were more likely to have uncontrolled seizure. Therefore, more emphasis should be given to these patients.

Entities:  

Mesh:

Year:  2018        PMID: 30478263      PMCID: PMC6255833          DOI: 10.1038/s41598-018-35906-2

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


Introduction

Epilepsy is a chronic neurologic disorder characterized by repeated epileptic seizures attacks which result from paroxysmal uncontrolled discharges of neurons within the central nervous system[1-4]. The definition of epilepsy requires the occurrence of at least one epileptic seizure[3]. Epilepsy is a major public health problem that affects more than 50 million people worldwide, of whom, 80% were living in developing countries[5-8]. African countries are among the highly affected regions and it is estimated that ten million people live with epilepsy in Africa[7,8]. Likewise, Ethiopia is affected by epilepsy with a reported prevalence of 5.2/1000 population and annual incidence of 64 per 100,000 population[9,10]. Antiepileptic Drugs (AEDs) can be indicated for Patients who have had one or more epileptic seizures. The choice of therapy for the management of epilepsy varies depending on the type, frequency, and severity of the seizures[4,11]. Making an accurate diagnosis of the type of epilepsy is crucial to select the best therapy[8,11]. Majority of epileptic seizures are controlled with the optimal use of the currently available AEDs. However, about one-third remained uncontrolled despite optimal therapy[12,13]. Although most of the people with epilepsy can become seizure-free with the optimal use of drug therapy, the treatment outcome in the majority of epileptic patients remains unsatisfactory in resources limited countries[8]. Studies have shown that majority [80–90%] of the patients with epilepsy are not receiving appropriate treatment in developing countries[8,14]. A number of problems affect the provision of adequate treatment of epilepsy and these problems are more pronounced in developing countries. The major problems include; lack of qualified medical personnel, unavailability of medications, poor community knowledge and awareness, cultural beliefs, stigma, poor economy, lack of prioritization, and poor health system infrastructure[14-16]. Many studies have shown that inappropriate drug therapy and non-adherence were the leading causes of poor seizure control[17-19]. Several factors have been found to be associated with treatment outcome in epilepsy. These include; gender, age of seizure onset, type of epilepsy, seizure frequency, etiology of epilepsy, duration of epilepsy, electroencephalography abnormality and presence of comorbidities[14,20-22]. Poorly controlled seizure leads to impairment of quality of life, excessive bodily injury, neuropsychological impairment, social stigma, reduced marriage rates, poor education, reduced employment levels, and finally shortened lifespan[23-25]. Assessment of epileptic patient’s treatment outcome and its predictors is crucial to develop treatment optimization strategies and responsible care of patients as clinicians may have difficulty in identifying patients that are less likely to have controlled seizure. Although different studies have been conducted in different parts of the world, there is no adequate data on epilepsy treatment outcome and associated factors in Ethiopia. To our knowledge, there is no study in our particular setting. Hence, our study investigated the treatment outcome and associated factors among epileptic patients.

Methods

Study design, study setting and study period

A hospital-based cross-sectional study was conducted from March 2017 to May 2017 at the neurologic clinic of Ayder comprehensive specialized hospital (ACSH), which is the second largest public hospital in Ethiopia with a catchment population of about 10 million people. The study period was from March 2016 to May 2017.

Study participants

Adult patients (age ≥ 18 years) with the diagnosis of epilepsy who have been on regular follow- up for at least one year with at least one AED were included in the study. Patients were recruited into the study during their appointment for medication refilling. Patients were excluded if they had a follow-up period of less than one year, seriously ill to complete the interview, refused to give consent, and those with incomplete medical records. A total of 270 patients were included in the study using simple random sampling technique.

Data collection instrument and procedure

All consented epileptic patients who visited the hospital during the data collection period and fulfilled the inclusion criteria were included in the study. Data regarding sociodemographic, medication adherence, medication belief and experience were retrieved by interviewing patients using the standardized questionnaire. Respective medical and medication records were retrieved by reviewing patient’s medical record chart using data abstraction checklist. The clinical information of the patients during the last one year follow up period (starting from the date of interview during the data collection period until the last one year) were assessed. All patient were followed for one year to determine their clinical and treatment related characteristics We trained the data collectors about the objective of the study, methods of data collection including data extraction from patient charts as well as techniques of interviewing patients. Patients’ belief about their medication was assessed using the belief about medicines questionnaire (BMQ), which has been validated for use in deferent chronic illness group studies[26,27]. It is a self-reported questionnaire that contains two five-item scales assessing patients’ belief about the necessity of the prescribed medications for controlling their illness and their concerns about the potential adverse consequences of taking it. Accordingly, participants were considered to have strong medication necessity belief if the average sum of the five-item medication necessity scale score (ranging from 5–25) is above the midpoint. Conversely, if the score is below this point they were considered to have low medication necessity belief. Similarly, participants were considered to have strong concern belief about their medication adverse effect if the average sum of the five-item medication concern scale score (ranges from 5–25) is above the midpoint, otherwise, they were considered to have low medication concern belief. The overall patients’ belief about their medication is obtained by subtracting the average 5–item medication concerns scale score from the average sum of 5–item patient’s medication necessity scale score. If the difference is positive, the patient is said to have positive medication belief. Conversely, if it is negative, the patient is said to have negative medication belief. Medication adherence was assessed using Morisky’s medication adherence scale, which has been validated for use in chronic illness adherence assessment[28]. It is a self-reported questionnaire which contains eight adherence related questions, in which the total score ranges from 0 to 8 points. The degree of adherence was determined according to the score resulting from the sum of all items. Accordingly, medication adherence was considered as low, medium, and high if the total score is <6, 6 to <8, and 8 points, respectively. Epileptic patients were defined and identified according to the international league against Epilepsy (ILAE)[3]. Accordingly, the definition of epilepsy requires the occurrence of at least one epileptic seizure. Participants who had any chronic disease other than epilepsy were considered to have comorbidity. Epileptic patients were said to have psychiatric disorder comorbidity if they had confirmed diagnosis of psychiatric disorders such as depression, schizophrenia, mood disorders, and anxiety by psychiatrist according to Diagnostic and Statistical Manual of Mental Disorders (DSM-5)[29]. Treatment outcome was measured in terms of seizure control status and seizure frequency. In order to evaluate epilepsy treatment outcome, seizure status of the patients in the last one-year follow-up period was considered. Every patient was followed for one year to determine the frequency of seizure in the one-year follow-up period. Operationally, the seizure status was considered to be controlled if the patient had not experienced any seizure attacks in the last one year, and not controlled if the patient experienced one or more seizure attacks in the last one year follow up period.

Data analysis

Data were recorded into an EPI data management (version 4.2.0) and analyzed using the Statistical Package for the Social Science (SPSS version 21.0). Descriptive analysis was computed using frequency and mean (standard deviation, SD) for categorical and continuous variables, respectively. The frequency of seizure control status was determined. Multicollinearity was checked to test correlation among predictor variables using variance inflation factor (VIF) and none was collinear. A VIF < 8 was considered as a cut point for excluding collinearity. Independent variables with p < 0.2 in univariable binary logistic regression analysis were re-entered into a multivariable binary logistic regression model to identify predictors of treatment outcome in epilepsy. A p value of < 0.05 was considered statistically significant in all analyses.

Ethical approval and informed consent

This study was approved by the institutional review board (IRB) of Mekelle University, College of Health Sciences. The aim and protocol of the study were fully explained to all patients included in the study and written informed consent was obtained from all participants. The privacy of individual information was strictly preserved. All the methods were performed in accordance with approved institutional guidelines.

Results

Sociodemographic characteristics of the study participants

A total of 270 epileptic patients were included in this study and analyzed. Of whom, 62% were males and the mean (±SD) age was 30.31 ± 10.95 years. Majorities of the participants were unemployed (73%) and urban dwellers (60%). A large proportion of the participants attended primary and secondary school (30.7% and 51.9%, respectively). With regard to social drug use, 6.3%, 4.1%, and 4.4% of the participants were using alcohol, khat, and cigarette, respectively (Table 1).
Table 1

Socio–demographic characteristics of the participants (n = 270).

CharacteristicsNumber (%)
Gender, male168(62)
Age in years
   18–30163(60.4)
   31–6099(36.6)
   >608 (3)
Residence, urban162(60)
Educational level
   Illiterate29 (10.7)
   Primary education83(30.7)
   Secondary education140(51.9)
   College and above18(6.7)
Marital status
   Married70(25.9)
   Single162(60)
   Divorced24(8.9)
   Widowed14(5.2)
Employment status
   Employed73(27)
   Unemployed197(73)
Social drug use
   Abstain230(85.2)
   Alcohol17(6.3)
   khat11(4.1)
   Cigarette12(4.4)
Monthly income (in Ethiopian Birr)
   <=1500 birr141(52.2)
   >=1500 birr129(47.8)
Age at the time of first seizure
   <=1577(28.5)
   16–30108(40)
   31–4561(22.6)
   46–6021(7.8)
   >603(1.1)
Socio–demographic characteristics of the participants (n = 270).

Medication belief and adherence status of the participants

Our study reported that majority (70%) of the participants had strong necessity belief towards the importance of their medication while 35% had strong concern belief. Overall, 70% had a positive belief about their medication. More than half (51.5%) of the patients had low adherence to their prescribed medications (Table 2).
Table 2

Medication belief and adherence status of the participants (n = 270)

CharacteristicsNumber (%)
Medication necessity belief
   Strong necessity belief189(70)
   Low necessity belief81(30)
Medication concern belief
   Strong concern belief94(35)
   Low concern belief176(65)
Overall medication belief
   Negative belief81(30)
   positive belief189(70)
Level of medication adherence
   High adherence27(10)
   Medium adherence104(38.5)
   Low adherence139(51.5)
Medication belief and adherence status of the participants (n = 270)

Disease and treatment related characteristics

The mean (±SD) duration of epilepsy was 5.42 ± 3.08 years and the median (IQR) was 5(3–7) years with a range from 1 to 20 years. More than half (59.6%) of the participants had lived with epilepsy for five or more years and 37.8% had one or more comorbidities. The most commonly identified comorbidity among epileptic patients was psychiatric disorder (20.4%). Generalized tonic-clonic seizure (GTCS), 84.4% was the most commonly diagnosed type of epilepsy. Nearly half (48.5%) of the study participants were on monotherapy of AEDs. Our finding reported that 43% of the patients complained about adverse drug events (ADEs) related to their medication (Table 3).
Table 3

Clinical and treatment related characteristics of the participants (n = 270).

CharacteristicsNumber (%)
Presence of comorbidity
   No102(37.8)
   Yes168(62.2)
Commonly identified co morbidities
   Psychiatric disorder55(20.37)
   Migraine headache20(7.4)
   Hypertension15(6)
   Human immune deficiency virus (HIV)11(4)
   Others16(6)
Duration of epilepsy in years
   Mean ± SD5.42 ± 3.08
   Median (IQR)5(3–7)
   <5109(40.4)
   ≥5161(59.6)
Type of seizure
   GTCS220(81.5)
   Focal seizure36(13.3)
   Absence seizure5(1.9)
   Unclassified seizure9(3.3)
Number of AED(s)
   One131(48.5)
   Two125(46.3)
   Three14(5.2)
ADE
   Yes117(43.3)
   No153(56.7)

GTCS, General tonic-clonic seizure, AED, Anti-epileptic drug, ADE, Adverse drug event, SD, standard deviation, IQR, interquartile range.

Clinical and treatment related characteristics of the participants (n = 270). GTCS, General tonic-clonic seizure, AED, Anti-epileptic drug, ADE, Adverse drug event, SD, standard deviation, IQR, interquartile range.

Seizure frequency and treatment outcome

Out of the total, 46.6% participants had controlled seizure. Whereas, 38.5%, 8.8%, 5.9% had experienced seizure attacks 1–5 times, 6–10 times, and greater than 10 times, respectively (Table 4).
Table 4

Distribution of seizure frequency and seizure status of the participants (n = 270).

Frequency of seizure during the last one yearNumber (%)
0 126(46.6)
1–5 times104(38.5)
6–10 times24(8.8)
>10 times16(5.9)
Distribution of seizure frequency and seizure status of the participants (n = 270).

Factors associated with treatment outcome

Using univariable binary logistic regression analysis, epileptic patients with controlled seizure and uncontrolled were compared using the socio-demographic, disease and medication related characteristics. Accordingly, alcohol consumption [Crude odds ratio (COR): 4.51, 95% confidence interval (CI): 1.26–16.11], negative medication belief [COR: 3.28, 95%CI: 1.86–5.79], low medication adherence [COR: 16.69, 95%CI: 5.82–47.87], presence of comorbidities [COR: 3.54, 95%CI: 1.47–8.44], triple AED therapy [COR: 3.54, 95%CI: 1.47–8.44], and ADE [COR: 3.58, 95%CI: 2.16–5.95] were significantly associated with uncontrolled seizure (Table 5).
Table 5

Univariable logistic regression analysis of factors associated with treatment outcome of epileptic patients (n = 270).

VariablesTreatment outcomeCOR (95% CI)p-value
Controlled seizure, n (%)Uncontrolled seizure, n (%)
Gender, female42(15.5)60(22.2)1.43(0.87–2.35)0.160
Age category
18–3070(26)93(34)11
31–6051(19)48(18)0.71(0.43–1.17)0.178
>605(2)3(1)0.45(0.10–1.95)0.287
Age at seizure onset
<=1533(12.2)44(16.3)11
16–3050(18.5)58(21.5)0.87(0.48–1.57)0.643
31–4530(11.1)31(11.5)0.78(0.40–1.52)0.459
>4513(4.8)11(4.1)0.64(0.25–1.59)0.333
Residence, urban75(27.8)87(32.2)1.04(0.637–1.69)0.881
Marital status
Married70(26)92(34)11
Single37(13.7)33(12.2)1.47(0.84–2.59)0.177
Divorce10(3.7)14(5.2)1.57(0.62–4.01)0.346
Widowed9(3.3)5(2)0.62(0.19–2.05)0.435
Education
Illiterate13(4.8)16(5.9)1.54(0.47–5.02)0.475
Primary38(14.1)45(16.7)1.48(0.53–4.13)0.453
Secondary65(24.1)75(27.8)1.44(0.54–3.87)0.467
Tertiary10(3.7%)8(3)11
Employment status
Unemployed92(34.1)105(38.9)0.99(0.58–1.70)0.985
Employed34(12.6)39(14.4)11
Income (in Ethiopian birr)
=<150062(23.0)79(29.3)1.26(0.78–2.03)0.354
>150064(23.7)65(24.1)11
Duration of epilepsy
<5 year48(17.8)61(22.6)1.19(0.73–1.95)0.476
≥5 year78(28.9)83(30.7)11
Alcohol use
No123(45.6)130(48.1)11
Yes3(1)14(5.2)4.51(1.26–16.11)0.020
Smoking
No120(44.4)139(51.5)11
Yes6(2.2)5(2)0.81(0.24–2.71)0.726
Khat chewing
No122(45.2)136(50.4)11
Yes4(1.5)8(3)1.93(0.57–6.59)0.293
Medication belief
Positive belief104(38.5)85(31.5)11
Negative belief22(8.2)59(21.9)3.28(1.86–5.79)<0.001
Medication adherence
High adherence22(8.2)5(2)11
Medium adherence75(27.8)29(10.7)1.70(0.59–4.92)0.326
Low adherence29(10.7)110(40.7)16.69(5.82–47.87)<0.001
Co–morbidity
No115(42.6)53(19.6)11
Yes11(4.1)91(33.7)17.950(8.87–36.34)<0.001
Type of seizure
GTCS101(37.4)119(44.1)11
Focal seizure18(6.7)18(6.7)0.85(0.42–1.72)0.648
Absence seizure2(0.7)3(1)1.27(0.21–7.760.794
Unclassified seizure5(1.9)4(1.5)0.68(0.18–2.60)0.572
Number of AEDs
One68(25.2)60(22.2)11
Two50(18.5)59(21.9)1.34(0.80–2.23)0.266
Three8(3)25(9.3)3.54(1.47–8.44)0.004
ADE
No73(27)40(14.8)11
Yes53(19.6)104(38.5)3.58(2.16–5.95)<0.001

COD, Crude odds ratio, CI, Confidence interval, AED, antiepileptic drugs, ADE, adverse drug event, GTCS, Generalized tonic-clonic seizure.

Univariable logistic regression analysis of factors associated with treatment outcome of epileptic patients (n = 270). COD, Crude odds ratio, CI, Confidence interval, AED, antiepileptic drugs, ADE, adverse drug event, GTCS, Generalized tonic-clonic seizure. On further multivariable binary logistic regression model; Alcohol consumption [adjusted odd ratio (AOR): 14.87, 95% CI: 3.25–68.11], negative medication belief [AOR: 3.0, 95%CI: 1.31–6.71], low medication adherence [AOR: 11.52, 95%CI:3.25–40.82], and presence of comorbidities [AOR: 10.346, 95%CI: 4.387–24.399] were found to be predictors of uncontrolled seizure (Table 6).
Table 6

Multivariable logistic regression analysis of factors associated with treatment outcome among epileptic patients (n = 270).

PredictorsTreatment out comeAOR (95%CI)p-value
Controlled seizure, n (%)Uncontrolled seizure, n (%)
Gender, female42(16)60(21.9)1.78(0.87–3.71)0.114
Age category
18–3070(26)93(34)11
31–6051(19)48(18)0.79(0.22–2.92)0.726
>605(2)3(1)1.79(0.05–62.2)0.749
Marital status
Married70(26)92(34)11
Single37(13.7)33(12.2)1.55(0.40–6.08)0.526
Divorce10(3.7)14(5.2)1.24(0.31–5.01)0.761
Widowed9(3.3)5(2)0.73(0.05–9.74)0.808
Alcohol use
No123(45.6)130(48.1)11
Yes3(1)14(5.2)14.87(3.25–68.1)<0.001
Medication belief
Positive belief104(38.585(31.5)11
Negative belief22(8.2)59(21.9)3.00(1.301–6.71)0.009
Medication adherence
High adherence22(8.2)5(2)11
Medium adherence75(27.8)29(10.7)2.46(0.70–8.77)0.166
Low adherence29(10.7)110(40.7)11.52(3.25–40.82)<0.001
Comorbidity
No115(42.6)53(19.6)11
Yes11(4.1)91(33.7)10.35(4.40–24.40)<0.001
Number of AEDs
One68(25.2)60(22.2)11
Two50(18.5)59(21.9)1.09(0.51–2.32)0.819
Three8(3)25(9.3)1.84(0.57–5.96)0.310
ADE
No73(27)40(14.8)11
Yes53(19.6)104(38.5)2.132(0.891–5.102)0.089

AOD, Adjusted odds ratio, CI, Confidence interval, AED, antiepileptic drugs, ADE, adverse drug event.

Multivariable logistic regression analysis of factors associated with treatment outcome among epileptic patients (n = 270). AOD, Adjusted odds ratio, CI, Confidence interval, AED, antiepileptic drugs, ADE, adverse drug event.

Discussion

Currently, therapeutic advances have resulted in meaningful changes in the diagnosis and management of epilepsy[30]. However, the practice of epilepsy management is inconsistent in different countries depending on the available expertise and resource[8]. Although evidence has shown that a greater proportion of epileptic patients become seizure free with the optimal use of the available AEDs[8,11-13], less than half of the patients remain seizure free in our study. This could be attributed to the lack of qualified medical personnel, unavailability of medications, poor community knowledge and awareness, and poor health system infrastructure in our setting where resources are limited. Our finding is also quite different from a study done in Gonder, Ethiopia[31] in which 82% of the epileptic patients achieve seizure remission over 3 months follow-up period. This variation could be due to the difference in follow-up period (3 months vs. 12 months). In line with our study, the majority of the patients had uncontrolled seizure in other similar studies[32-34]. Several studies revealed that alcohol consumption is a risk factor for developing seizure and it increased the risk of seizure in epileptic patients[35-38]. Similarly, alcohol was found to be a predictor of uncontrolled seizure in our study. This could be explained that alcohol consumption could lead to sleep deprivation, missing meals, missing medications and increase the side effect of AED which were reported as triggering factors of seizure[14,35-38]. Hence, much should be done on awareness of alcohol use of epileptic patients. Our finding reported that low medication adherence was significantly associated with uncontrolled seizure. In agreement to our study, many studies have shown that non-adherence to medication was the leading cause poor epilepsy control[14,17,19,31,32,39]. In addition, our study revealed that patients with a negative medication belief were less likely to have seizure free period compared to those with a positive medication belief. The possible justification for this could be patients with a negative medication belief are less likely to adhere to their medications as revealed by our study and other similar studies[40,41]. Hence, educational programs should be designed to improve the perception of patients about their medication as well as their medication adherence. Our study also reported that epileptic patients with comorbidity were less likely to have controlled seizure than those without comorbidities which is in line other similar studies[41-43]. Thus, more emphasis should be given to these patients. Patients with a triple AED therapy and those who experienced ADEs were less likely to have seizure-free period though statistically not significant on the multivariable regression model. Even though evidence-based guidelines recommend the use of monotherapy for the majority of epileptic patients[41,44,45], only 48.5% were maintained on monotherapy in our study. Overall, utilization of monotherapy was found to be low compared to other similar studies[14,46,47]. This could be due to the absence of specific epilepsy treatment guideline and lack of expertise of healthcare professionals in our setup. Our study reported that 43% of the patients had experienced ADE related to their AED therapy. This finding is higher compared to the studies conducted in Gonder (17.6%) and Jimma (33.4%); Ethiopia[31,48]. This could be attributed to the higher use of multiple AED therapy in our setting. Finally, our study is not without limitations. The cross-sectional nature of the study may not provide adequate evidence of causality regarding seizure control status and its predictors. Due to self-report concerns, patients may understate socially undesirable activities like medication non-adherence and negative medication belief.

Conclusion

Our findings revealed that more than half of the epileptic patients have uncontrolled seizure. Epileptic patients with a negative medication belief, comorbidities, low medication adherence and those who consume alcohol were more likely to have uncontrolled seizure. Therefore, particular consideration should be given to these potentially modifiable risk factors. Educational programs about the importance of their medication, adherence, and precipitating factors such as alcohol should be given. Moreover, we recommend researchers to do further longitudinal and interventional studies with more strong study design to provide adequate evidence about the cause-effect relationship between the predictor variables and seizure control.
  36 in total

1.  The treatment of epilepsy in developing countries: where do we go from here?

Authors:  R A Scott; S D Lhatoo; J W Sander
Journal:  Bull World Health Organ       Date:  2003-07-02       Impact factor: 9.408

2.  The outcome of initiation of antiepileptic drug monotherapy in primary care: a UK database survey.

Authors:  Christopher Ll Morgan; Scot Buchan; Michael P Kerr
Journal:  Br J Gen Pract       Date:  2004-10       Impact factor: 5.386

3.  Antiepileptic drug utilization in Taiwan: analysis of prescription using National Health Insurance database.

Authors:  Liang-Po Hsieh; Chin-Yin Huang
Journal:  Epilepsy Res       Date:  2009-01-09       Impact factor: 3.045

4.  Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE).

Authors:  Robert S Fisher; Walter van Emde Boas; Warren Blume; Christian Elger; Pierre Genton; Phillip Lee; Jerome Engel
Journal:  Epilepsia       Date:  2005-04       Impact factor: 5.864

Review 5.  Drug-resistant epilepsy.

Authors:  Patrick Kwan; Steven C Schachter; Martin J Brodie
Journal:  N Engl J Med       Date:  2011-09-08       Impact factor: 91.245

Review 6.  Recent advances in epilepsy.

Authors:  Mark Manford
Journal:  J Neurol       Date:  2017-01-24       Impact factor: 4.849

Review 7.  The new definition and classification of seizures and epilepsy.

Authors:  Jessica J Falco-Walter; Ingrid E Scheffer; Robert S Fisher
Journal:  Epilepsy Res       Date:  2017-11-28       Impact factor: 3.045

8.  Prevalence and Factors Associated with Perceived Stigma among Patients with Epilepsy in Ethiopia.

Authors:  Tolesa Fanta; Telake Azale; Dawit Assefa; Mekbit Getachew
Journal:  Psychiatry J       Date:  2015-09-06

9.  Drug therapy of epileptic seizures among adult epileptic outpatients of University of Gondar Referral and Teaching Hospital, Gondar, North West Ethiopia.

Authors:  Eshetie Melese Birru; Miftah Shafi; Mestayet Geta
Journal:  Neuropsychiatr Dis Treat       Date:  2016-12-16       Impact factor: 2.570

10.  Adherence to Treatment and Factors Affecting Adherence of Epileptic Patients at Yirgalem General Hospital, Southern Ethiopia: A Prospective Cross-Sectional Study.

Authors:  Temesgen Yohannes Hasiso; Tigestu Alemu Desse
Journal:  PLoS One       Date:  2016-09-29       Impact factor: 3.240

View more
  13 in total

1.  Magnitude, Symptom Presentation and Correlates of Psychological Distress Among People with Epilepsy in Southern Ethiopia: A Cross-Sectional Study.

Authors:  Birhanie Mekuriaw; Bahru Mantefardo; Alemayehu Molla; Getasew Berhanu; Tsegaye Mehare; Zelalem Belayneh
Journal:  Neuropsychiatr Dis Treat       Date:  2020-09-18       Impact factor: 2.570

Review 2.  A systematic review and meta-analysis of anti-epileptic medication non-adherence among people with epilepsy in Ethiopia.

Authors:  Zelalem Belayneh; Birhanie Mekuriaw
Journal:  Arch Public Health       Date:  2020-05-01

3.  The treatment outcomes of epilepsy and its root causes in children attending at the University of Gondar teaching hospital: A retrospective cohort study, 2018.

Authors:  Addisu Beyene; Agumas Fentahun Ayalew; Getasew Mulat; Ayele Simachew Kassa; Tigabu Birhan
Journal:  PLoS One       Date:  2020-03-12       Impact factor: 3.240

4.  Treatment response and predictors in patients with newly diagnosed epilepsy in Ethiopia: a retrospective cohort study.

Authors:  Kidu Gidey; Legese Chelkeba; Tadesse Dukessa Gemechu; Fekede Bekele Daba
Journal:  Sci Rep       Date:  2019-11-07       Impact factor: 4.379

5.  Epilepsy Treatment Outcome and Its Predictors among Ambulatory Patients with Epilepsy at Mizan-Tepi University Teaching Hospital, Southwest Ethiopia.

Authors:  Ameha Zewudie; Yitagesu Mamo; Desalegn Feyissa; Mohammed Yimam; Gosaye Mekonen; Ahmed Abdela
Journal:  Neurol Res Int       Date:  2020-04-08

6.  Adherence to Antiepileptic Drugs among Patients Attending the Neuro Spinal Hospital in the United Arab Emirates.

Authors:  Enas S Abd Wahab; Muaed Al Omar; Moawia M A M Altabakha
Journal:  J Pharm Bioallied Sci       Date:  2020-10-08

7.  Change in the Frequency of Seizure Attacks and Associated Factors Among Adult Epilepsy Patients at Amanuel Mental Specialized Hospital (AMSH): A Generalized Linear Mixed Model (GLMM).

Authors:  Temam Beshir Raru; Bisrat Misganaw Geremew; Koku Sisay Tamirat
Journal:  Neuropsychiatr Dis Treat       Date:  2021-08-04       Impact factor: 2.570

8.  Seizure control status and associated factors among pediatric epileptic patients at a neurologic outpatient clinic in Ethiopia.

Authors:  Habtamu Digis Adal; Kassahun Alemu; Esileman Abdela Muche
Journal:  PLoS One       Date:  2021-11-03       Impact factor: 3.240

Review 9.  Treatment Outcome of Epileptic Patients Receiving Antiepileptic Drugs in Ethiopia: A Systematic Review and Meta-Analysis.

Authors:  Taklo Simeneh Yazie; Belayneh Kefale; Mulugeta Molla
Journal:  Behav Neurol       Date:  2021-05-13       Impact factor: 3.342

10.  Health-related quality of life and its determinants among ambulatory patients with epilepsy at Ambo General Hospital, Ethiopia: Using WHOQOL-BREF.

Authors:  Gosaye Mekonen Tefera; Worku Asefa Megersa; Diriba Alemayehu Gadisa
Journal:  PLoS One       Date:  2020-01-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.